Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 35.59M | 36.35M | 29.36M | 40.11M | 39.45M |
Gross Profit | 25.13M | 21.95M | 15.40M | 29.06M | 28.40M |
EBITDA | -19.26M | -29.18M | -30.00M | -22.01M | -9.71M |
Net Income | -20.72M | -28.51M | -32.81M | -24.56M | -7.84M |
Balance Sheet | |||||
Total Assets | 47.37M | 53.26M | 63.23M | 89.52M | 89.95M |
Cash, Cash Equivalents and Short-Term Investments | 3.28M | 14.13M | 22.14M | 52.14M | 71.42M |
Total Debt | 26.89M | 18.31M | 18.25M | 13.82M | 1.03M |
Total Liabilities | 36.26M | 29.99M | 27.86M | 26.94M | 10.73M |
Stockholders Equity | 11.11M | 23.28M | 35.38M | 62.58M | 79.22M |
Cash Flow | |||||
Free Cash Flow | -14.71M | -22.59M | -34.69M | -18.29M | -7.29M |
Operating Cash Flow | -14.43M | -21.66M | -28.23M | -14.01M | -5.61M |
Investing Cash Flow | -669.43K | -936.24K | -6.46M | -4.28M | -1.68M |
Financing Cash Flow | 9.33M | 14.47M | 4.96M | 715.20K | 66.35M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $98.50M | 12.78 | 5.00% | ― | 0.29% | -22.13% | |
64 Neutral | $87.65M | 48.13 | 3.46% | ― | 24.75% | -61.29% | |
56 Neutral | $74.75M | ― | -113.95% | ― | 8.49% | 6.09% | |
53 Neutral | $81.73M | ― | -67.86% | ― | 0.34% | 6.20% | |
51 Neutral | $7.30B | 0.27 | -62.71% | 2.44% | 15.02% | 0.60% | |
50 Neutral | $79.83M | ― | -26.20% | ― | 20.81% | -498.66% | |
43 Neutral | $56.98M | ― | -94.65% | ― | -5.86% | 50.76% |
On July 2, 2025, CytoSorbents Corporation announced regulatory updates regarding its DrugSorb-ATR device. The U.S. FDA scheduled an appeal hearing for the company’s supervisory review, while Health Canada issued a Notice of Refusal for the Medical Device License application due to non-compliance issues. CytoSorbents plans to address these concerns through the appeals process, aiming for final regulatory decisions by the end of 2025. The company believes DrugSorb-ATR offers a unique solution for reducing perioperative bleeding in cardiac surgery, addressing a critical need in the U.S. and Canadian markets.
The most recent analyst rating on (CTSO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.
On June 24, 2025, CytoSorbents Corporation announced its decision to appeal the U.S. FDA’s denial of its De Novo Request for DrugSorb-ATR, a device designed to reduce bleeding severity in patients undergoing coronary artery bypass grafting. The company filed for a supervisory review on June 18, 2025, aiming to resolve deficiencies identified by the FDA and believes a final regulatory decision can be achieved in 2025. The appeal process involves engaging with FDA senior leadership and external experts, reflecting CytoSorbents’ confidence in addressing the FDA’s concerns. Meanwhile, the DrugSorb-ATR application with Health Canada is under advanced review, with a decision expected in 2025 despite delays.
The most recent analyst rating on (CTSO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.
CytoSorbents Corporation held its 2025 Annual Meeting of Stockholders on June 12, 2025, where stockholders voted on several key matters. The election of five directors was confirmed, the compensation of named executive officers was approved on a non-binding basis, and the appointment of WithumSmith+Brown, PC, as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions reflect the company’s ongoing governance and operational strategies, impacting its leadership structure and financial oversight.
The most recent analyst rating on (CTSO) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.
On June 11, 2025, CytoSorbents Corporation announced that the 5-day volume weighted average price per share of its common stock was below the required minimum of $2.00, leading to the expiration of the Series B Right Warrants issued in a prior Rights Offering. Consequently, payments made for the exercise of these warrants will be refunded without interest or penalty.
The most recent analyst rating on (CTSO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.